Lung Cancer Clinical Trials in Detroit

Showing 181-200 of 342 trials

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

NCT04151563

This study is for participants with Non-small Cell Lung Cancer that has spread or has reoccurred after failure of Chemotherapy and Immunotherapy

Carcinoma, Non-small Cell Lung Cancer

Bristol-Myers SquibbStarted Apr 2021

Detroit, Michigan, United States • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina • Buenos Aires, Distrito Federal, Argentina +20 more locations

COMPLETEDPHASE1/PHASE2< 1 mile

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

NCT03602079

Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity.

HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more

Klus Pharma Inc.49 participantsStarted Jul 2018

Sarasota, Florida, United States • Boston, Massachusetts, United States • Detroit, Michigan, United States +7 more locations

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Lung Cancer Trials in Other Cities

Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

Radiation in Stage I or Stage II Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

The Lung Screening, Tobacco and Health Project

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Survival Prolongation by Rationale Innovative Genomics

Other Conditions in Detroit